SecBot SecBot

PAVM

PAVmed Inc.
Nasdaq· Surgical & Medical Instruments & Apparatus· Inc. DE· CIK 0001624326 Healthcare & Medical Devices
$2.26 +0.09 (+4.15%)
Oct 26 4:00 PM ET · prev $2.17
Market cap
$16.4M
Nano cap
Consensus
Buy
88% Buy or better · 8 analysts
Median target
$36.50
+1515% · range $16.00–57.00
Next earnings
Nov 10
in 15 days · EPS est. −$0.66
1 year
−83.2%
from $13.44 · Oct 27
30 days
−40.4%
from $3.80
52-week range
$2.05–13.44
−83% from high · low Oct 22
Avg volume 20D
20.8K
Oct 1 spike 187.7K
Short interest
12.6K
≈0.2% of shares · +16.7%
Days to cover
1.0
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read MIXED 2 reports · 90 days
Balance 0 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 2/2 ·Next Earnings date, Nov 10, 2026
Strongest NEUTRAL PAVmed Inc. disclosed that its subsidiary, Lucid Diagnostics Inc., raised $15.0 million through the sale of…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q2 2026: 6 added (0 new), 0 trimmed or exited.

  • AnalystsBULLISH

    7 of 8 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.690 → −$0.660 over 90 days. 0 up, 1 down in 30 days.

  • Short sellersBUILDING

    Short interest +16.7% to 12.6K shares. 1.0 days to cover, ≈0.2% of shares.

  • TrendDOWNTREND

    41% below its 50-day average. New closing low $2.05 on Oct 22.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
FIRST MANHATTAN CO. LLC.DOUBLED332,911$2.0M
VANGUARD CAPITAL MANAGEMENT LLCDOUBLED61,604$365.9K
GEODE CAPITAL MANAGEMENT, LLCDOUBLED36,678$217.9K
VANGUARD FIDUCIARY TRUST CODOUBLED25,605$152.1K
BlackRock, Inc.DOUBLED17,092$101.5K
Steward Partners Investment Advisory, LLCDOUBLED2$12.00
VANGUARD GROUP INCADD342,171$75.6K
UBS Group AGDOUBLED219,813$48.6K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

8 analysts
Buy 88% rate it Buy or better
Strong Buy2Buy5Hold1Sell0Strong Sell0
12-month targets · 2 analysts

Price is below the lowest target. Median implies +1515%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Aug 27, 2026Ascendiant Capital
MAINTAIN
MAINTAINBuy
Jun 8, 2026Ascendiant Capital
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Apr 2, 2026
Aklog Lishan
Chairman and CEO
AWARD350,000 sh
Apr 2, 2026
MCGRATH DENNIS M
President and CFO
AWARD180,000 sh
Apr 2, 2026
Agrawal Sundeep
Director
AWARD13,930 sh
Apr 2, 2026
Baxter Timothy E
Director
AWARD13,930 sh
Apr 2, 2026
O'Neil Shaun
Chief Operating Officer
AWARD110,000 sh
Apr 2, 2026
Glennon Michael J
Director
AWARD13,930 sh
Apr 2, 2026
Lee Victoria Tou-ho
Chief Medical Officer
AWARD70,000 sh
Apr 2, 2026
Sparks Ronald M
Director
AWARD13,930 sh

Earnings setup

Estimates
Nov 10
reports in 15 days
−$0.66
EPS estimate, this quarter
+4%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.66-$0.66–-$0.66-4.8%$25.0K
Next Q-$0.64-$0.64–-$0.64-4.9%$130.0K
Current FY-$2.33-$2.33–-$2.33+11.1%$232.5K
Next FY-$2.38-$2.38–-$2.38+2.9%$600.0K

Short side

FINRA· Sep 30, 2026
12,621
shares short
+16.7%
vs prior settlement
1.0
days to cover
≈0.2%
of shares outstanding
Trading halts
Jul 23, 2026Volatility PauseResumed
Jul 16, 2026Volatility PauseResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 23, 2026 SEC
Craig Kallman and his trust filed an amendment to their Schedule 13G, disclosing a 4.9% passive stake in PAVmed Inc…
SC 13G/A — Impact 3/10
Oct 22, 2026 SEC
PAVmed Inc. disclosed that its subsidiary, Lucid Diagnostics Inc., raised $15.0 million through the sale of 15,000…
8-K — Impact 5/10
Aug 11, 2026 Earnings calendar
PAVM Q2 2026 Earnings Scheduled — 2026-08-11
Jun 30, 2026 Inst.
FIRST MANHATTAN CO. LLC. — DOUBLED
332,911 shares ($2.0M)
Jun 30, 2026 Inst.
VANGUARD CAPITAL MANAGEMENT LLC — DOUBLED
61,604 shares ($365.9K)
May 15, 2026 SEC
PAVmed reported Q1 2026 revenue of $22K (up from $8K YoY) but GAAP net loss attributable to common stockholders…
8-K — Impact 6/10
Apr 2, 2026 Insider
Aklog Lishan was granted 350,000 shares
Chairman and CEO
Apr 2, 2026 Insider
MCGRATH DENNIS M was granted 180,000 shares
President and CFO
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 10, 2026
Earnings date
PAVM Q3 2026 Earnings Scheduled — 2026-11-10
Recent
Aug 11, 2026
Earnings date
PAVM Q2 2026 Earnings Scheduled — 2026-08-11
Jul 23, 2026
Trading halt
Halt Resumed: PAVM — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-07-23T15:21:02.000Z | Resumed 2026-07-23T15:36:02.000Z
Jul 23, 2026
Trading halt
Trading Halt: PAVM — LUDP (Volatility Trading Pause)
PAVmed Inc. Common Stock | Market: NASDAQ | Code: LUDP — Volatility Trading Pause
Jul 16, 2026
Trading halt
Halt Resumed: PAVM — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-07-16T13:40:30.000Z | Resumed 2026-07-16T13:45:30.000Z
Jul 16, 2026
Trading halt
Trading Halt: PAVM — LUDP (Volatility Trading Pause)
PAVmed Inc. Common Stock | Market: NASDAQ | Code: LUDP — Volatility Trading Pause

SecBot reports

4 filings · 0 bullish · 1 bearish · 3 neutral
All PAVM filing & press-release reports (4)